MEDICINE ON LINE
CLINICAL TRIAL

¨ CARE Trial

Cholesterol and Recurrent Events

CARE trial is a 5-year study, involving 4159 patients, survived a myocardial infarct.
In the Pravastatin-treated group, there was a 25% reduction in relative risk of having another coronary event.
The relative risk of needing coronary artery bypass or angioplasty was reduced by 32%.

A post doc subgroup analysis shows that non-diabetic patients defined as glucose intolerant, who received Pravastatin had a lower rate of coronary events than patients given placebo.

[Sacks V et al. Circulation 1998; 98: 2513-2519]

---

¨ DIAMOND

Danish Investigation of Arrhythmia and Mortality on Dofetilide

The trial has enrolled 3.000 patients.
Dofetilide is a selective potassium channel blocker.

---

¨ REDUCE Trial

Reduction of restenosis after PTCA, early administration of Reviparin in a double-blind, unfractioned heparin and placebo controlled evaluation.

Early clinical events following PTCA

In the setting of the REDUCE trial, 306 patients were randomized to receive unfractionated heparin / placebo (UFH / placebo) and 306 patients to receive Reviparin, a low molecular weight heparin. Clinical follow-up was obtained for 601 patients.

Home page MEDILINE.net